Abstract 136P
Background
TNBC is more likely to metastasize within 3-5 years than other forms of breast cancer and has a median survival of 17.6-21.3 months after metastasis. Recent advances are promising, but trial results of immunotherapy-chemo combinations have resulted in a 3-year overall survival rate under 36% in a PD-L1 based cohort. There is thus an unmet need for innovations that lead to new treatments and improve outcomes for patients with TNBC in a personalized manner.
Methods
We have developed a platform to identify predictors of drug efficacy in TNBC. We assembled a panel of TNBC models that were screened with a library of 387 compounds. We integrated these results with multiomic molecular characterization to identify significant correlates of response to therapy. We used a panel of RNA correlates to characterize treatment naive PDXs to predict response to one of the most promising drugs, SN-38, a known active drug in TNBC. We evaluated SN-38 in vivo to ensure our in vitro screening was indicative of response.
Results
Following screening, we prioritized 35 drugs based on their activity and variance of response, identifying statistically significant molecular correlates of drug response for 27 out of 35 (77%) compounds. Focusing on SN-38, we identified a panel of multiomic correlates of response. Utilizing rapid RNA profiling, we predicted the response of previously untested PDXs to SN-38. Ex vivo evaluation of 5 PDXs revealed that our predictions were correlated with actual response. We identified that the autophagy and AKT pathways were elevated in models with poor response to SN-38; specific co-targeting these pathways with SN-38 was an effective strategy to identify rational, synergistic combinations. In vivo evaluation of irinotecan (SN-38 pro-drug) demonstrated correlation between our assayed response in vitro and response in mice.
Conclusions
We developed a platform that identified multiomic correlates of drug response for 27 compounds in TNBC. These correlates demonstrate promise in the prediction of response in molecularly unknown samples as well as the identification of companion therapeutics to synergize with a given therapy and help prevent or delay resistance. Going forward, we are working on the in vivo validation of these predictions of response and companion therapy combinations.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Breast Cancer Research Foundation, Susan G. Komen.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - Event-free survival prediction using lncRNAs in pediatric B-cell acute lymphoblastic leukemia
Presenter: Unai Illarregi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Exome sequencing analysis for the identification of actionable mutations related to neoadjuvant chemotherapy response in locally advanced breast cancer
Presenter: Ximena López
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection
Presenter: Abderaouf Hamza
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Correlation of EZH2 expression and response to chemoradiotherapy in patients with locally advanced inoperable oral cavity and oropharyngeal squamous cell cancers
Presenter: Soel Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - Predictive value of DNA damage response and repair gene alterations and neoscore for neoadjuvant immunotherapies in non-small cell lung cancer
Presenter: Fei Feng
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - Immune-related epigenomic and transcriptomic signatures to predict immunotherapy response in NSCLC
Presenter: María Gallardo-Gómez
Session: Cocktail & Poster Display session
Resources:
Abstract
142P - Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - Genomic characterization and outcomes of patients with primary sclerosing cholangitis-related cholangiocarcinoma
Presenter: Jaime Haro Silerio
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract